A self-promo roundup of his newsletter topics, from retatrutide trial results to his own peptide protocol. Little detail beyond the list.
Recap by typeshit. Post by Jesse Morse, M.D. on X.
The once-daily pill blocks the IL-23 receptor and helped people with moderate to severe ulcerative colitis respond more often than placebo, a new study reports.
Bikman welcomes a new result but argues the likely cause is tirzepatide bringing insulin down rather than the drug slowing aging itself. His view, not a study claim.
Marchione makes the case for pairing GLP-1s with drugs that target amylin, the hormone released after meals that signals fullness to the brain.
Regen says the placebo group saw a 9% drop, while people on retatrutide also lost 31 lb on average and saw systolic blood pressure fall 14 points.
The market research firm credits GLP-1 demand for a projected 9.5% yearly growth rate, with Asia Pacific expected to grow fastest.
Men's Health looks at why some people lose hair on GLP-1 drugs, how long it tends to last, and the treatments it suggests to limit it.
Loading…